Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
2017-004009-42Phase 2Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of prexasertib in ovarian cancer (3 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Overall response rate. Status: unknown.
02
Drugs
prexasertib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2017-004009-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004009-42.